BioSpace News Archive

“Today, the Government of Canada released national-level modelling on the COVID-19 epidemic in Canada. The modelling attempts to show how the epidemic might unfold over the coming months based on our knowledge of how the virus behaves and the potential impact of public health measures.

BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America, today announced that the Board of Directors has appointed Joseph Truitt as interim Chief Executive Officer.

Hepatitis C virus infection is of particular concern in patients with chronic kidney disease. There is a much higher prevalence of HCV infection in the CKD/end-stage kidney disease population than is found in the general population.

ArtemiLife Inc. announced today a collaboration with the Potsdam, Germany based Max Planck Institute of Colloids and Interfaces.

BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in North America, today announced that its Board of Directors appointed Mike Sherman and Corey Fishman to serve as Independent Directors, effective immediately.

New formulations enable oral delivery of therapeutics traditionally delivered intravenously

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the first quarter 2020 and provided updates in response to the COVID-19 pandemic.

Tango Therapeutics , today announced the closing of an oversubscribed Series B financing of $60 million led by Boxer Capital of the Tavistock Group. Cormo

April 9, 2020 12:00 UTC X4 Pharmaceuticals to Present and Participate in the Virtual 19 th Annual Needham Healthcare Conference

FirstWave Bio, Inc., a clinical-stage biotechnology company developing novel gut-targeted small molecules for inflammatory bowel disease and other serious conditions, today announced plans to initiate a Phase 2a/2b study in patients with COVID-19, beginning in mid-2020.